Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LEGEND STRATEGY INTERNATIONAL HOLDINGS GROUP COMPANY LIMITED
枂濬國際集團控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1355)

COMPLETION ANNOUNCEMENT DISCLOSEABLE TRANSACTION THE ACQUISITION OF IN RELATION SHARES IN TO AURO HONG KONG LIMITED

Reference is made to the announcements of Legend Strategy International Holdings Group Company Limited (the "**Company**") dated 23 December 2025 and 3 March 2026 (the "**Announcements**") in relation to the Acquisition. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE ACQUISITION

The Company is pleased to announce that all of the conditions precedent to the Sale and Purchase Agreement have been satisfied and the Completion took place on 6 March 2026 in accordance with the terms of the Sale and Purchase Agreement. As a result, the Group holds 37.5% equity interest in Beisheng Biotechnology.

By order of the Board
Legend Strategy International Holdings Group Company Limited
Lee Tsz Yan
Executive Director

Hong Kong, 6 March 2026

As at the date of this announcement, the Board comprises Ms. Lee Tsz Yan as executive Director; Mr. Cheung Ching Ho and Mr. Hu Xinglong as non-executive Directors; Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.